Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Fineline Cube Sep 8, 2026
Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Fineline Cube Sep 8, 2026
Company

Jiangsu Hengrui Pharmaceuticals Reports 9.19% YOY Revenue Growth in H1 2023 Financial Report

Fineline Cube Aug 21, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has released its financial report for the first...

Drug

AstraZeneca’s Forxiga Gains New Indication Approval in China for Chronic Heart Failure

Fineline Cube Aug 21, 2023

UK-based pharmaceutical major AstraZeneca plc (AZ, NASDAQ: AZN) has announced that China’s National Medical Products...

Company Deals

Hua Medicine Achieves Development Milestone for HuaTangNing with Bayer Agreement

Fineline Cube Aug 21, 2023

China-based Hua Medicine (HKG: 2552) has announced the achievement of a significant development milestone for...

Company Drug

MSD’s Welireg Meets Primary Endpoint in Phase III RCC Study but Misses OS Milestone

Fineline Cube Aug 21, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has revealed that the ongoing Phase III study...

Company Deals

CARsgen Therapeutics Partners with Moderna to Combine CAR-T Therapy with mRNA Cancer Vaccine

Fineline Cube Aug 21, 2023

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced a collaboration agreement with US mRNA...

Company Deals

Simcere Pharmaceutical Group Secures Exclusive Rights to CMAB009 in China

Fineline Cube Aug 21, 2023

Simcere Pharmaceutical Group Ltd (HKG: 2096) has announced that its subsidiary, Jiangsu Simcere Zaiming Pharmaceutical...

Company Deals

Ezisurg Medical Partners partners with Vathin for Global Disposable Endoscope strategic partnership

Fineline Cube Aug 21, 2023

Ezisurg Medical Co., Ltd has announced a strategic partnership with Hunan Vathin Medical Instrument Co.,...

Company

Fosun Pharma Adjusts Investment Allocation for 2022 Non-Public Offering Projects

Fineline Cube Aug 21, 2023

Fosun Pharma (SHA: 600196) has declared adjustments to the investment amounts for some of its...

Company Drug

HutchMed’s Sovleplenib Achieves Primary and Secondary Endpoints in ESLIM-01 Phase III Trial

Fineline Cube Aug 21, 2023

China-based biopharmaceutical company HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that the pivotal...

Company Drug

Grand Pharmaceutical Group Initiates Phase I Study for Sepsis Treatment APAD

Fineline Cube Aug 18, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the enrollment and dosing of the...

Company Drug

HutchMed’s Orpathys Receives Breakthrough Therapy Designation in China for Gastric Cancer

Fineline Cube Aug 18, 2023

HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that its MET inhibitor, Orpathys (savolitinib),...

Policy / Regulatory

Henan Leads 19-Province Alliance for Volume-Based Drug Procurement Tender

Fineline Cube Aug 18, 2023

A new inter-provincial alliance, led by Henan, has formed a 19-strong group to conduct a...

Company Drug

Humanwell Healthcare Initiates Phase IIa Clinical Study for IPF Drug HW021199

Fineline Cube Aug 18, 2023

China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced the commencement of a Phase...

Company Drug

GSK’s RSV Vaccine Arexvy Launches in US Pharmacies Ahead of 2023/24 Season

Fineline Cube Aug 18, 2023

GlaxoSmithKline (GSK; NYSE: GSK), a UK-based pharmaceutical giant, has announced that its respiratory syncytial virus...

Company Deals

Eyebright Medical Technology Plans GRD Listing on SIX Exchange to Raise RMB 1.4 Billion

Fineline Cube Aug 18, 2023

Eyebright Medical Technology Co., Ltd (SHA: 688050), a Beijing-based company specializing in ophthalmic medical devices,...

Company Drug

GC Biopharma Presents Data Showing Higher Thrombotic Risk with Roche’s Hemlibra

Fineline Cube Aug 18, 2023

South Korea’s GC Biopharma (KRX: 006280) has presented evidence suggesting that Roche’s (SWX: ROG) hemophilia...

Company Drug

Moderna Announces Immunogenicity of Updated COVID-19 Vaccine Against New Variants

Fineline Cube Aug 18, 2023

Moderna (NASDAQ: MRNA) has announced preliminary data indicating that an updated version of its SARS-CoV-2...

Company

Tigermed Establishes International Headquarters in Hong Kong to Accelerate Global Expansion

Fineline Cube Aug 18, 2023

China-based Contract Research Organization (CRO) Tigermed (SHE: 300347, HKG: 3347) has announced the opening of...

Company Medical Device

NMPA Approves Rapid Medical Ltd’s Intracranial Thrombectomy Stent for Marketing

Fineline Cube Aug 18, 2023

The National Medical Products Administration (NMPA) has granted marketing approval to Rapid Medical Ltd for...

Company Drug

Luye Pharma Launches Rykindo in US, a First for Chinese CNS Drug

Fineline Cube Aug 18, 2023

China-based Luye Pharma Group (HKG: 2186) has announced the official commercial operation of its Rykindo...

Posts pagination

1 … 538 539 540 … 717

Recent updates

  • Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management
  • Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform
  • METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker
  • Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent
  • Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Others

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.